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Abstract: Introduction: Previous studies have demonstrated that glycosaminoglycan hyaluronic acid
(HA) is capable of mediating oral tumor growth. Some clinical evidence has suggested reduced
HA expression predicts poor cancer prognosis and that HA-chemotherapy conjugates may function
synergistically to inhibit oral tumor growth. Other studies have found conflicting results that suggest
enhanced CD44-HA-mediated growth and proliferation. Due to the lack of clarity regarding HA
function, the primary goal of this study was to investigate the effects of HA using well-characterized
oral cancer cell lines. Methods: Using several commercially available oral squamous cell carcinoma
lines (and a normal non-cancerous control), 96-well growth and viability assays were conducted
using HA (alone and in combination with chemotherapeutic agents paclitaxel and PD98059). Results:
Different results were observed in each of the cell lines evaluated. HA induced small, non-significant
changes in cellular viability among each of the cell lines within a narrow range (1–8%), p = 0.207.
However, HA induced differing effects on growth, with minimal, non-significant changes among
some cell lines, such as SCC4 (+1.7%), CCL-30 (−2.8%), and SCC15 (−2.5%), p = 0.211 and more robust
inhibition among other cell lines, SCC9 (−24.4%), SCC25 (−36.6%), and CAL27 (−47.8%), p = 0.0001.
Differing effects were also observed with growth and viability under concomitant administration of
HA with PD98059 or paclitaxel. Further analysis of these data revealed strong inverse (Pearson’s)
correlations between initial baseline growth rate and responsiveness to HA administration, ranging
from R = −0.27 to R = −0.883. Conclusion: The results of this study revealed differing responses to
HA, which may be inversely correlated with intrinsic characteristics, such as the baseline growth
rate. This may suggest that the more rapidly growing cell lines are more responsive to combination
therapy with hyaluronic acid; an important finding that may provide insights into the mechanisms
responsible for these observations.
Keywords: oral cancer; hyaluronic acid; chemotherapy; paclitaxel

1. Introduction
Previous studies have demonstrated that the glycosaminoglycan hyaluronic acid (HA) is capable
of mediating oral tumor growth [1–3]. For example, recent studies of liver and pancreatic cancers have
demonstrated the role of the tumor microenvironment and HA, more specifically, to modulate
growth and progression [4,5]. This has led to an increased need to understand not only the
phenotypic-modulating potential of HA but also the interactive effects of chemotherapeutic-based
treatments involving HA co-administration [6,7].
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Some evidence from clinical studies has suggested reduced HA expression may be sufficient
to provide diagnostic and prognostic information for different types of cancer, including breast
and bladder cancers [8–10]. More recent evidence has suggested the prognostic and therapeutic
implications of HA expression may also be useful in some subsets of oral cancers [11,12]. For example,
in HPV-negative tumors, these studies revealed that high levels of stromal HA expression were, in fact,
predictors of poor clinical outcomes and reduced survival, which may be a function of interactions with
the extracellular matrix (ECM) and HA, in particular [1,11]. For example, some evidence now suggests
that degradation of HA by hyaluronidase (HAase) in some head and neck tumors may function to
create smaller fragments capable of stimulating angiogenesis—a strong negative indicator of survival
and outcome among oral cancer patients [13,14].
Despite these findings, much remains to be discovered regarding the therapeutic potential
of HA for oral cancer treatment. For example, some evidence has suggested improved clinical
outcomes for chemotherapeutic delivery with HA [15], while others have found more complicated and
conflicting results [16]. This evidence may suggest that combination therapies with HA might facilitate
chemotherapeutic potential, although much remains to be evaluated regarding which patients and
specific clinical pathophysiologic indications are most appropriate for the use and administration of
HA [17,18]. Based upon the conflicting nature of studies in this area, the primary goal of this study
was to investigate the effects of HA (alone and in combination with chemotherapeutic agents) using
well-characterized oral cancer cell lines.
2. Methods
2.1. Cell Culture
Several commercially available cell lines were obtained from the American Type Culture Collection
(ATCC; Manassas, VA, USA), which included the oral squamous cell carcinoma (SCC) lines SCC4
(CRL-1624), SCC9 (CRL-1629), SCC15 (CRL-1623), SCC25 (CRL-1628), and CAL27 (CRL-2095). The nasal
septum carcinoma line CCL-30 (RMPI-2650) and normal non-cancerous oral gingival cells HGF-1
(CRL-2014) were also obtained (Table 1).
Table 1. Verification and cross-checking of cell lines.
Cell Line

Catalog Reference

STR % Match

Cell Type

HGF-1
SCC4
SCC9
SCC15
SCC25
CAL27
CCL-30

CRL-2014
CRL-1624
CRL-1629
CRL-1623
CRL-1628
CRL-2095
RPMI-2650

100%
92%
100%
94%
100%
93%
100%

Normal oral
Oral squamous cell carcinoma
Oral squamous cell carcinoma
Oral squamous cell carcinoma
Oral squamous cell carcinoma
Oral squamous cell carcinoma
Nasal septum carcinoma

Available cell lines were verified and cross-checked against the International Cell Line
Authentication Committee (ICLAC) database to ensure these were not among the currently known
cross-contaminated or misidentified cell lines. Short tandem repeat (STR) profiling results for these cell
lines were compared using the eight STR loci from the ATCC database for cell line authentication.
In brief, cells were thawed and cultured according to the recommended protocol from the supplier
(ATCC). CAL27, CCL-30, and HGF-1 cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) modified to contain 10% fetal bovine serum (FBS) and 1% penicillin–streptomycin. The other
oral cancer cell lines (SCC4, SC9, SCC15, SCC25) were cultured in a 1:1 mixture of Dulbecco’s modified
Eagle’s medium and Ham’s F12 medium containing 1.2 g/L sodium bicarbonate, 2.5 mM L-glutamine,
15 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPE)S and 0.5 mM sodium pyruvate.
All cells were maintained in a humidified biosafety level-2 (BSL-2) tissue culture chamber. Experiments
were performed with cells between passages five and passage ten.
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2.2. Reagents
Hyaluronic acid (HA) was obtained from MP Biomedicals (ThermoFisher Scientific; Fair Lawn,
NJ, USA, CAS 9004-61-9) with a molecular weight (MW) of 776.651 g/mol. One chemotherapeutic
agent used in other HA-combination therapies studies of head and neck cancers [17], paclitaxel (PTX)
or Taxol, was obtained from ACROS Organics (ThermoFisher Scientific, CAS 33069-62-4) with an MW
of 853.9 g/mol. A positive control, the cellular mitogen-activated protein kinase (MAP) kinase (MEK)
inhibitor PD98059, was obtained from Invitrogen (ThermoFisher Scientific, Catalog number PHZ1164)
with an MW of 267.3 Daltons (Da).
2.3. Cellular Viability
The viability of cells was determined at the beginning and end of each experimental assay using
the trypan blue exclusion assay. In brief, a trypan blue 0.4% solution (Gibco) was added to control and
experimental cells to create a 1:1 dilution, which was incubated at room temperature. Each plate was
placed on a hemocytometer grid on a Zeiss Axiovert inverted microscope (Carl Zeiss AG, Oberkochen,
Germany). Four to six grids (1.0 mm2 ) were counted and averaged to determine cell number. To verify
these results, control and experimental cells were also trypsinized and diluted 1:1 with trypan blue for
viability using a BioRad TC20 automated cell counter (Bio-Rad Laboratories, Hercules, CA, USA).
2.4. Proliferation Assays
Cells were plated in 96-well tissue culture plates at a density of 1.2 × 105 cells/mL and allowed
to grow for 24, 48, and 72 h. Experimental cells were treated with 10 ng/mL of PD98059, paclitaxel
(Taxol), or both in the presence or absence of hyaluronic acid (10 ng/well), which were administered
concomitantly at the beginning of each experimental trial. Cells were subsequently fixed with 10%
formalin and stained using Gentian violet. Absorbance readings for each plate were measured using a
BioTek ELx808 (BioTek, Winooski, VT, USA) microplate reader at 595 nm to approximate cell number
and confluence.
2.5. Statistical Analysis
Differences between continuous variables (absorbance readings) were calculated using parametric
statistical analysis methods, including two-tailed Student’s t-tests and an alpha level of 0.05 to determine
significance. All experiments were performed in triplicate with n = 8 from each experimental trial for a
total n = 24 for all experimental conditions.
3. Results
Cell cultures were established for each cell line, and viability was determined to establish the
baseline before experimentation (Table 2). In brief, the viability of all cell lines ranged from 74% to
93%—with the highest viability observed among the oral squamous cell carcinomas. For example,
SCC25, SCC15, SCC9, and CAL27 exhibited viability of 93%, 91%, 89%, and 89%, respectively.
One additional oral cancer cell line (SCC4) and the nasal carcinoma (CCL-30) exhibited slightly lower
viability (82% and 74%, respectively). The normal human gingival fibroblast cell line HGF-1 exhibited
a viability of 88%.
To determine any effects of hyaluronic acid on survival, cells were plated in 96-well assays,
and average viability was measured each day over three days (Figure 1). These data revealed that no
significant differences were found in cellular viability between the control and experimental cell lines,
p = 0.207. More specifically, a few cell lines exhibited small but not significant increases in viability,
including HGF-1 (+8%), SCC9 (+3%), CCL-20 (+1%), and CAL27 (+1%), while others exhibited slight
decreases in viability (SCC4, −1%; SCC15, −3%, SCC25, −1%).
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Table 2. Establishment of Experimental Cell Cultures.

Cell
J. Funct. Biomater. 2020, 11,
72 Line

Confluence
Live Cell Count
SCC25 (oral cancer)
1.33 × 105 cells/mL 1.23 × 105 cells/mL
SCC9 (oral cancer)
7.70 × 104 cells/mL 7.01 × 104 cells/mL
Table
2.
Establishment
Experimental
SCC15 (oral cancer)
8.60 × 104 of
cells/mL
7.65 Cell
× 104Cultures.
cells/mL
5
5 cells/mL
CAL27
(oral
cancer)
1.52
×
10
cells/mL
1.35
×
10
Cell Line
Confluence
Live Cell Count
CCL-30 (nasal cancer)
5.68 ×5 104 cells/mL 4.66 × 1045cells/mL
SCC25 (oral cancer)
1.33 × 10 cells/mL
1.23 × 10 cells/mL
SCC4 (oral cancer)
7.17 × 104 cells/mL 5.31 × 104 cells/mL
4
SCC9
(oral (normal
cancer) gingiva)7.704.33
× 10× 10
cells/mL
7.01 ××10
1044cells/mL
cells/mL
4 cells/mL
HGF-1
3.81
SCC15 (oral cancer)

8.60 × 104 cells/mL

7.65 × 104 cells/mL

CAL27 (oral cancer)

1.52 × 105 cells/mL

1.35 × 105 cells/mL

Viability
93%
91%
89%
89%
Viability
82%
93%
74%
88%91%
89%
Ave: 86.2%
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4 cells/mL
SCC4
(oral cancer)
74%
7.17
104 cells/mL
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More
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while
others
Ave: 86.2%
exhibited slight decreases in viability (SCC4, −1%; SCC15, −3%, SCC25, −1%).

HA

Cell line

Control (CTL)
Viability %

Experiment (HA)

Statistical analysis

HGF-1 (normal gingiva)

80%

88%

P=0.207

SCC4 (oral cancer)

76%

75%

P=0.714

CCL-30 (nasal cancer)

81%

82%

P=0.731

CAL27 (oral cancer)

88%

89%

P=0.774

SCC15 (oral cancer)

92%

89%

P=0.455

SCC9 (oral cancer)

88%

91%

P=0.541

SCC25 (oral cancer)

93%

92%

P=0.833
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Following each measurement of viability, cells were also processed to measure growth to determine
any effects of hyaluronic acid on proliferation (Figure 2). These data revealed different effects on
growth that did not correlate with the effects on cellular viability. For example, some cells did not
exhibit any significant changes to cellular growth between the control and experimental (HA) assays,
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Statistical analysis

SCC9 (oral cancer)

(NP) PD98059 -12.3%
(NP) Paclitaxel -33.1%

(HA) PD98059 -13.3%
(HA) Paclitaxel -17.0%

P=0.774
P=0.018*

SCC25 (oral cancer)

(NP) PD98059 -12.3%
(NP) Paclitaxel -16.8%

(HA) PD98059 -19.2%
(HA) Paclitaxel -25.0%

P=0.033*
P=0.028*

SCC15 (oral cancer)

(NP) PD98059 -44.0%
(NP) Paclitaxel -29.7%

(HA) PD98059 -16.2%
(HA) Paclitaxel -23.8%
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P=0.041
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(NP) PD98059 -8.9%
(NP) Paclitaxel -12.1%
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(NP) PD98059 -17.1%
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P=0.023*
P=0.025*
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Statistical analysis

SCC9 (oral cancer)

(NP) PD98059 -19.5%
(NP) Paclitaxel -34.5%

(HA) PD98059 -20%
(HA) Paclitaxel -24.4%
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P=0.015*
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Table 3. Correlation of cellular phenotype responsiveness to hyaluronic acid (HA).
Cell Line

Baseline
Growth (3d)

Viability
PD98059+HA

Viability
Paclitaxel+HA

Growth
PD98059+HA

Growth
Paclitaxel+HA

CAL27

1.4

−18

−4.8

−29.9

−13.6

SCC25

1.2

−6.9

−8.2

−30.9

−38.9

SCC15

0.8

16.1

5.9

27.7

4.1

SCC9

0.76

−1

16.1

−0.5

10.1

SCC4

0.58

1.8

−17.3

16.8

−9.7

CCL-30

0.55

11.1

10.7

18.11

17

R = −0.80026

R = −0.27006

R = −0.8831

R = −0.68196

Correlation

4. Discussion
The primary goal of this study was to investigate the effects of hyaluronic (alone and in combination
with chemotherapeutic agents) using well-characterized oral cancer cell lines to determine any potential
effects on cellular phenotypes, such as growth and viability. The results of this study revealed differing
responses to both phenotypes, which may be inversely correlated with intrinsic characteristics, such as
the baseline growth rate. This may suggest that the more rapidly growing cell lines are more responsive
to combination therapy with hyaluronic acid; an important finding that may provide insights into the
mechanisms responsible for these observations.
For example, one recent study demonstrated synergistic effects similar to those observed in this
study with combination cisplatin–hyaluronic acid treatment in advanced metastatic ovarian cancer [19].
Another study also found that combination therapy involving hyaluronic acid exhibited synergistic
and enhanced anti-tumor effects among aggressive breast cancers [20]. These data may suggest the
results of this study may be consistent with other studies of combination therapies using hyaluronic
acid with other aggressive and metastatic tumors.
In addition, these results may suggest that the extracellular matrix (ECM)-mediated responses
may, in fact, play significant roles in tumor responsiveness to chemotherapy [21,22]. This may be
due to the expression of hyaluronidases and matrix metalloproteinases, such as MMP-2 and MMP-9,
among advanced and metastatic cancers that cleave ECM (including hyaluronic acid) and reduce
cell-ECM contacts, adhesion, and the associated intracellular signaling [23,24]. In addition, this may
also suggest that expression of MMP-2 and MMP-9 may serve as a biomarker or indicator to determine
if combination therapy, including hyaluronic acid, may be indicated—although more research will be
needed to make these determinations [25].
Although some previous studies have suggested that high expression of HA in both tumor and
stromal cells from resected oral cancer patients may correlate with poor prognosis [11,14], these studies
also confirm previous observations that proteolytic cleavage of HA by hyaluronidases and matrix
metalloproteinases (MMPs) may trigger the invasion and metastasis via the receptor for hyaluronan
(HA)-mediated motility (RHAMM) CD44 [18,25]. In fact, some evidence now suggests that CD44 acts
as a receptor for proteolytically-modified HA and may be responsible for the modulation of intracellular
signaling associated with increased proliferation and invasive capacity [17,26,27]. However, because
the production of proteolytic enzymes with their cognate targets may be tightly regulated within
these tumors, administration of intact, exogenous HA and the delivery of chemotherapeutic agents
conjugated with HA has been sufficient in clinical studies to improve patient outcomes and reduce
metastatic phenotypes in many cancer types [17,18,28–30].
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5. Conclusions
Although much remains to be elucidated, these findings suggest that hyaluronic acid may, in fact,
exert different effects in oral squamous cell carcinomas. Elucidation of the factors that more accurately
determine oral cancer responsiveness, such as CD44, MMP-2, MMP-9, and hyaluronidase expression,
may be needed to allow oral healthcare researchers and clinicians to more accurately assess and treat oral
cancers with the most efficient and effective means of treatment that may include combination therapy
with hyaluronic acid. Because this study revealed differential responses, which may be inversely
correlated with intrinsic characteristics, such as baseline growth rate, the analysis and identification
of those factors that correlate with responsiveness to combination therapy with hyaluronic acid may
provide important insights into the mechanisms responsible for these observations.
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˛
D.A.; Wcisło-Dziadecka, D. Physiochemical properties and
application of hyaluronic acid: A systematic review. J. Cosmet. Dermatol. 2016, 15, 520–526. [CrossRef]
Safdar, M.H.; Hussain, Z.; Abourehab, M.A.; Hasan, H.; Afzal, S.; Thu, H.E. New developments and clinical
transition of hyaluronic acid-based nanotherapeutics for treatment of cancer: Reversing multidrug resistance,
tumour-specific targetability and improved anticancer efficacy. Artif. Cells Nanomed. Biotechnol. 2017, 46,
1–14. [CrossRef]
Velesiotis, C.; Vasileiou, S.; Vynios, D.H. A guide to hyaluronan and related enzymes in breast cancer:
Biological significance and diagnostic value. FEBS J. 2019, 286, 3057–3074. [CrossRef]
Pawar, A.; Prabhu, P. Nanosoldiers: A promising strategy to combat triple negative breast cancer.
Biomed. Pharmacother. 2019, 110, 319–341. [CrossRef]
Morera, D.S.; Hennig, M.S.; Talukder, A.; Lokeshwar, S.D.; Wang, J.; Garcia-Roig, M.; Ortiz, N.; Yates, T.J.;
Lopez, L.E.; Kallifatidis, G.; et al. Hyaluronic acid family in bladder cancer: Potential prognostic biomarkers
and therapeutic targets. Br. J. Cancer 2017, 117, 1507–1517. [CrossRef]
Sun, D.S.; Won, H.S.; Hong, S.A.; Hong, J.H.; Jo, H.; Lee, H.; Kim, O.; Lee, M.A.; Ko, Y.H. Prognostic
implications of stromal hyaluronic acid protein expression in resected oropharyngeal and oral cavity cancers.
Korean J. Int. Med. 2019, 35, 408–420. [CrossRef]

J. Funct. Biomater. 2020, 11, 72

12.
13.

14.

15.

16.
17.

18.

19.

20.

21.

22.

23.

24.

25.

26.

27.
28.

10 of 11

Xing, R.-D.; Chang, S.-M.; Li, J.-H.; Li, H.; Han, Z.-X. Serum hyaluronan levels in oral cancer patients.
Chin. Med. J. 2008, 121, 327–330. [CrossRef] [PubMed]
Kosunen, A.; Ropponen, K.; Kellokoski, J.; Pukkila, M.; Virtaniemi, J.; Valtonen, H.; Kumpulainen, E.;
Johansson, R.; Tammi, R.; Tammi, M.; et al. Reduced expression of hyaluronan is a strong indicator of poor
survival in oral squamous cell carcinoma. Oral Oncol. 2004, 40, 257–263. [CrossRef] [PubMed]
Franzmann, E.J.; Schroeder, G.L.; Goodwin, W.J.; Weed, D.T.; Fisher, P.; Lokeshwar, V.B. Expression of tumor
markers hyaluronic acid and hyaluronidase (HYAL1) in head and neck tumors. Int. J. Cancer 2003, 106,
438–445. [CrossRef] [PubMed]
Shi, X.-L.; Li, Y.; Zhao, L.-M.; Su, L.-W.; Ding, G. Delivery of MTH1 inhibitor (TH287) and MDR1 siRNA via
hyaluronic acid-based mesoporous silica nanoparticles for oral cancers treatment. Colloids Surf. B Biointerfaces
2019, 173, 599–606. [CrossRef] [PubMed]
Simone, P.; Alberto, M. Caution Should be Used in Long-Term Treatment with Oral Compounds of Hyaluronic
Acid in Patients with a History of Cancer. Clin. Drug Investig. 2015, 35, 689–692. [CrossRef] [PubMed]
Galer, C.E.; Sano, D.; Ghosh, S.C.; Hah, J.H.; Auzenne, E.; Hamir, A.N.; Myers, J.N.; Klostergaard, J.
Hyaluronic acid–paclitaxel conjugate inhibits growth of human squamous cell carcinomas of the head and
neck via a hyaluronic acid-mediated mechanism. Oral Oncol. 2011, 47, 1039–1047. [CrossRef]
Wang, S.J.; Bourguignon, L.Y.W. Hyaluronan-CD44 Promotes Phospholipase C–Mediated Ca2+ Signaling
and Cisplatin Resistance in Head and Neck Cancer. Arch. Otolaryngol. Head Neck Surg. 2006, 132, 19.
[CrossRef]
Shariati, M.; Lollo, G.; Matha, K.; Descamps, B.; Vanhove, C.; Van De Sande, L.; Willaert, W.; Balcaen, L.;
Vanhaecke, F.; Benoit, J.-P.; et al. Synergy between Intraperitoneal Aerosolization (PIPAC) and Cancer
Nanomedicine: Cisplatin-Loaded Polyarginine-Hyaluronic Acid Nanocarriers Efficiently Eradicate Peritoneal
Metastasis of Advanced Human Ovarian Cancer. ACS Appl. Mater. Interfaces 2020, 12, 29024–29036. [CrossRef]
Chong, Y.; Huang, J.; Xu, X.; Yu, C.; Ning, X.; Fan, S.; Zhang, Z. Hyaluronic Acid-Modified Au-Ag
Alloy Nanoparticles for Radiation/Nanozyme/Ag+ Multimodal Synergistically Enhanced Cancer Therapy.
Bioconjug. Chem. 2020, 31, 1756–1765. [CrossRef]
Xiao, W.; Wang, S.; Zhang, R.; Sohrabi, A.; Yu, Q.; Liu, S.; Ehsanipour, A.; Liang, J.; Bierman, R.D.;
Nathanson, D.A.; et al. Bioengineered scaffolds for 3D culture demonstrate extracellular matrix-mediated
mechanisms of chemotherapy resistance in glioblastoma. Matrix Boil. 2020, 86, 128–146. [CrossRef]
Tang, J.; Wang, N.; Wu, J.; Ren, P.; Li, J.; Yang, L.; Shi, X.; Chen, Y.; Fu, S.; Lin, S. Synergistic effect and reduced
toxicity by intratumoral injection of cytarabine-loaded hyaluronic acid hydrogel conjugates combined with
radiotherapy on lung cancer. Investig. New Drugs 2019, 37, 1146–1157. [CrossRef] [PubMed]
Palumbo, A.; Da Costa, N.M.; Pontes, B.; Oliveira, F.L.; Codeço, M.L.; Pinto, L.F.R.; Nasciutti, L.E. Esophageal
Cancer Development: Crucial Clues Arising from the Extracellular Matrix. Cells 2020, 9, 455. [CrossRef]
[PubMed]
Spinelli, F.M.; Vitale, D.L.; Icardi, A.; Caon, I.; Brandone, A.; Giannoni, P.; Saturno, V.; Passi, A.; García, M.;
Sevic, I.; et al. Hyaluronan preconditioning of monocytes/macrophages affects their angiogenic behavior and
regulation of TSG-6 expression in a tumor type-specific manner. FEBS J. 2019, 286, 3433–3449. [CrossRef]
[PubMed]
Parashar, P.; Tripathi, C.B.; Arya, M.; Kanoujia, J.; Singh, M.; Yadav, A.; Saraf, S.A. A facile approach for
fabricating CD44-targeted delivery of hyaluronic acid-functionalized PCL nanoparticles in urethane-induced
lung cancer: Bcl-2, MMP-9, caspase-9, and BAX as potential markers. Drug Deliv. Transl. Res. 2019, 9, 37–52.
[CrossRef]
Shen, S.; Lu, H.; Liu, L.; Wang, Y.; Zhang, C.; Yang, W.; Xu, W. Role of CD44 in tumor-initiating cells of
salivary gland pleomorphic adenoma: More than a surface biomarker. Oral Dis. 2020, 26, 547–557. [CrossRef]
[PubMed]
Shigeishi, H.; Higashikawa, K.; Takechi, M. Role of receptor for hyaluronan-mediated motility (RHAMM) in
human head and neck cancers. J. Cancer Res. Clin. Oncol. 2014, 140, 1629–1640. [CrossRef]
Jung, S.; Jung, S.; Kim, D.-M.; Lim, S.-H.; Shim, Y.-H.; Kwon, H.; Kim, D.H.; Lee, C.-M.; Kim, B.-H.;
Jeong, Y.-I. Hyaluronic Acid-Conjugated with Hyperbranched Chlorin e6 Using Disulfide Linkage and
Its Nanophotosensitizer for Enhanced Photodynamic Therapy of Cancer Cells. Materials 2019, 12, 3080.
[CrossRef]

J. Funct. Biomater. 2020, 11, 72

29.

30.

11 of 11

Kim, D.E.; Kim, C.W.; Lee, H.J.; Min, K.H.; Kwack, K.H.; Lee, H.-W.; Bang, J.; Chang, K.; Lee, S.C. Intracellular
NO-Releasing Hyaluronic Acid-Based Nanocarriers: A Potential Chemosensitizing Agent for Cancer
Chemotherapy. ACS Appl. Mater. Interfaces 2018, 10, 26870–26881. [CrossRef]
Litwiniuk, M.; Krejner, A.; Speyrer, M.S.; Gauto, A.R.; Grzela, T. Hyaluronic Acid in Inflammation and Tissue
Regeneration. Wounds 2016, 28, 78–88.
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).

